



2015-05-29

**PRESS RELEASE**

**Communiqué from Oasmia's Extraordinary General Meeting 2015**

**Oasmia Pharmaceutical AB (publ.), with VAT no SE556332-667601, held its Extraordinary General Meeting on Thursday, May 28, 2015, where the following main resolutions were made. For detailed information about the content of the resolutions, see the complete notice for the Extraordinary General Meeting which is available on Oasmia's website [www.oasmia.com](http://www.oasmia.com), together with the complete proposals for the resolutions below.**

*The Board of Directors*

The General Meeting resolved that the Board shall consist of Julian Aleksov, Bo Cederstrand, Hans Sundin, Alexander Kotsinas, Horst Domdey, Hans Liljeblad, Lars Bergkvist until the next General Meeting. Julian Aleksov was elected as Executive Chairman of the Board.

*Authorization for the Board to make decisions on issue of new shares and convertible debt instruments*

The General Meeting made a resolution, in accordance with the proposal by the Board, to authorize the Board to on one or more occasions during the period to, on one or several occasions for the period up to the next annual general meeting of shareholders, resolve on an issue of shares, warrants and/or convertible instruments. The board of directors shall be authorized to adopt decisions on an issue of shares, warrants and/or convertible instruments with deviation from the shareholders' pre-emption rights and/or an issue in kind or an issue by way of set-off or otherwise on such terms and conditions as referred to in Chapter 2, Section 5, second paragraph, points 1-3 and 5, of the Swedish Companies Act. The new shares, warrants and/or convertible instruments shall, in the event of a deviation from the shareholders' pre-emption rights, be issued at a subscription price which connects to the stock price at the time of the issue, decreased by a market rate discount that the board of directors deems necessary (if any).

The reason that the board of directors shall be authorized to resolve on an issue with deviation from the shareholders' pre-emption rights and/or an issue in kind or an issue by way of set-off or otherwise on such terms and conditions as referred to above is that the Company shall be able to issue shares, warrants and/or convertible instruments in connection with acquisitions of companies or businesses and to carry-out directed issues in order to raise capital or broaden the ownership of the Company. The board of directors shall however not be entitled to make resolutions which entail that the share capital is increased with more than SEK 1,500,000 (in addition to the increase in share capital which may arise due to a previous authorization which also is valid up to the next annual meeting of shareholders).

It is also proposed that the board, or any person appointed by the board, is authorized to make such minor adjustments to this resolution that may be necessary in connection with the registration with the Swedish Companies Registration Office or Euroclear Sweden AB.

**For more information, please contact:**

Anders Lundin, Chief Financial Officer  
Mobile: +46 70 20 96 300  
E-mail: anders.lundin@oasmia.com

**Notes to editors**

**About Oasmia Pharmaceutical AB**

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

---

Information is also available at [www.oasmia.com](http://www.oasmia.com) [www.nasdaqomxnordic.com](http://www.nasdaqomxnordic.com) [www.boerse-frankfurt.de](http://www.boerse-frankfurt.de) [twitter.com/oasmia](https://twitter.com/oasmia)

*"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08.15, CET on May 29, 2014."*